Structure Therapeutics Inc.
GPCRDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
2 upcoming, 1 past
GPCR Earnings Report
EPS Est: $-0.39 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How GPCR's past catalysts played out
GSBR-1290
Overweight or Obesity
Aleniglipron
Obesity, Overweight, or Chronic Weight Management
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GSBR-1290 | Phase 2 | Overweight or Obesity | - | - |
Aleniglipron | Phase 2 | Obesity, Overweight, or Chronic Weight Management | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Structure Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Structure Therapeutics Inc.'s (GPCR) pipeline across Phase 2. Its lead program is GSBR-1290 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Structure Therapeutics Inc.'s next FDA catalyst?→
Structure Therapeutics Inc.'s (GPCR) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GPCR biotech catalysts?→
Add GPCR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Structure Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.